Company news
Innoviva, Inc. news in 2022
Innoviva, Inc.'s news releases, calls and decks from 2022, newest first.
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
November 29, 2022
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 8, 2022
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022
October 18, 2022
La Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022
October 13, 2022
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022
October 11, 2022
Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 7, 2022
Innoviva Completes Acquisition of La Jolla Pharmaceutical
August 21, 2022
Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
July 26, 2022
Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment
July 12, 2022
Innoviva to Acquire La Jolla Pharmaceutical Company
July 10, 2022
Innoviva Completes Acquisition of Entasis Therapeutics
July 10, 2022
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
July 7, 2022
Innoviva to Acquire Entasis Therapeutics
May 22, 2022
Innoviva Reports First Quarter 2022 Financial Results
April 26, 2022
Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva
March 30, 2022
Innoviva, Inc. Prices Upsized Offering of $225 Million of 2.125% Convertible Senior Notes
March 2, 2022
Innoviva Announces Proposed Offering of $200 Million of Convertible Senior Notes
March 1, 2022
Innoviva Reports Fourth Quarter 2021 Financial Results
February 8, 2022
Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Development
February 8, 2022
Decks in 2022
- Investor Presentation (September 2022)
Investor deck · 21 slides · Sep 14, 2022
- Investor Presentation (April 2022)
Investor deck · 22 slides · Apr 7, 2022